MNG900
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.457
- OXIDATIVE_PHOSPHORYLATION+0.375
- DNA_REPAIR+0.370
- INTERFERON_ALPHA_RESPONSE+0.350
- CHOLESTEROL_HOMEOSTASIS+0.322
- INFLAMMATORY_RESPONSE+0.318
- MYC_TARGETS_V1+0.297
- P53_PATHWAY+0.275
- INTERFERON_GAMMA_RESPONSE+0.266
- ALLOGRAFT_REJECTION+0.255
Top 10 suppressed
- MITOTIC_SPINDLE-0.476
- PROTEIN_SECRETION-0.377
- G2M_CHECKPOINT-0.337
- PI3K_AKT_MTOR_SIGNALING-0.317
- HEDGEHOG_SIGNALING-0.313
- ANDROGEN_RESPONSE-0.233
- APICAL_JUNCTION-0.206
- GLYCOLYSIS-0.204
- HEME_METABOLISM-0.179
- ESTROGEN_RESPONSE_EARLY-0.167
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-A6JD-01A-11R-A31N-07 | — | — | 0.723 |
| 2 | C9C70D33-C09B-4F7E-8F12-FDE51817038A | — | — | 0.713 |
| 3 | cddceb59-733b-48d1-9b75-46c9949f7794 | — | — | 0.688 |
| 4 | TCGA-CV-A45T-01A-11R-A24H-07 | — | — | 0.688 |
| 5 | 21f65654-07a2-4b27-b511-2497fa298d0e | — | — | 0.687 |
| 6 | b2b53efa-8a7b-4871-b6bb-6ebfb5cc0cea | — | — | 0.676 |
| 7 | MDT-AP-2585 | Med | Medulloblastoma | 0.662 |
| 8 | MNG580 | — | — | 0.661 |
| 9 | MDT-AP-2172 | Med | Medulloblastoma | 0.659 |
| 10 | 65DAB913-D39C-4AC4-BB1C-10E58914571F | — | — | 0.657 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.457 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.375 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.370 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.350 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.322 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.318 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.297 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.275 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.266 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.255 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.251 | Inavolisib | — uncovered |
| COAGULATION | 0.248 | Binimetinib | — uncovered |
| MYOGENESIS | 0.214 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.186 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.176 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.154 | Inavolisib | — uncovered |
| APOPTOSIS | 0.131 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.128 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.115 | Temsirolimus | — uncovered |
| PEROXISOME | 0.107 | Idelalisib | — uncovered |